Get the Stockscreener App
3.32
0.00%
0.00
After Hours:
3.33
0.01
+0.30%
Embecta Corp stock is traded at $3.32, with a volume of 1.76M.
It is up +0.00% in the last 24 hours and down -63.95% over the past month.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
See More
Previous Close:
$3.32
Open:
$3.32
24h Volume:
1.76M
Relative Volume:
1.04
Market Cap:
$196.97M
Revenue:
$1.04B
Net Income/Loss:
$111.90M
P/E Ratio:
1.6852
EPS:
1.9701
Net Cash Flow:
$205.80M
1W Performance:
+5.73%
1M Performance:
-63.95%
6M Performance:
-77.21%
1Y Performance:
-68.40%
1-Day Range:
$3.225
$3.41
1-Week Range:
$2.77
$3.41
52-Week Range:
$2.77
$15.55
Embecta Corp Stock (EMBC) Company Profile
Name
Embecta Corp
Sector
Industry
Phone
(862) 401-0000
Address
300 KIMBALL DRIVE, PARSIPPANY
Compare EMBC vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EMBC
Embecta Corp
|
3.32 | 196.97M | 1.04B | 111.90M | 205.80M | 1.9701 |
ISRG
Intuitive Surgical Inc
|
438.10 | 155.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.63 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.78 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.01 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
208.05 | 30.31B | 5.54B | 1.52B | 1.74B | 10.37 |
Embecta Corp Stock (EMBC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Nov-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | Wolfe Research | Peer Perform |
| Jan-06-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-08-22 | Initiated | BTIG Research | Neutral |
| Aug-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-22 | Initiated | BofA Securities | Underperform |
View All
Embecta Corp Stock (EMBC) Latest News
EMBC PE Ratio & Valuation, Is EMBC Overvalued - Intellectia AI
Embecta (EMBC) Hit With A Sharp Target Cut As Medtech Sentiment Weakens - Yahoo Finance
Why Embecta stock plummeted today - MSN
Embecta acquires Owen Mumford for $172.6m - MSN
EMBC SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Carroll County Mirror-Democrat
Embecta closes $200M Owen Mumford acquisition - NJBIZ
Embecta Corp. (EMBC) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Embecta Corp stock (US29082K1051): analyst price cut and sliding share price put diabetes specialist - AD HOC NEWS
EMBC Maintained by B of A Securities -- Price Target Lowered to $3.00 - GuruFocus
Forvis Mazars advises on sale of Owen Mumford to US-listed Embecta - Accountancy Today
Embecta Price Target Cut to $3.00/Share From $11.00 by B of A Securities - Moomoo
Embecta closes Owen Mumford acquisition for up to $201M - MedTech Dive
Embecta Is Maintained at Underperform by B of A Securities - Moomoo
Embecta completes Owen Mumford acquisition - Drug Delivery Business
BofA Securities Adjusts Price Target on Embecta to $3 From $11 - Moomoo
Embecta (EMBC) price target decreased by 24.00% to 12.92 - MSN
Embecta Corp stock (US29082K1051): diabetes specialist updates investors after recent earnings - AD HOC NEWS
User | poteaudailynews.comEmbecta Corp.Common Stock (Nasdaq:EMBC) Stock Quote - FinancialContent
Embecta faces US reset as CEO bets on GLP-1, Owen Mumford diversification - MSN
Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification - MarketBeat
Embecta Completes Owen Mumford Acquisition to Expand Devices - The Globe and Mail
About Us | Oil & Gas JournalEmbecta Corp.Common Stock (Nasdaq:EMBC) Stock Quote - FinancialContent
Embecta: Owen Mumford Acquisition Completed - Pulse 2.0
Embecta completes acquisition of Owen Mumford to expand drug delivery and chronic care device offerings. - Pluang
Embecta Completes Acquisition of Owen Mumford to Expand Global Drug Delivery and Chronic Care Device Portfolio - Minichart
Embecta (Nasdaq: EMBC) closes up to £150M Owen Mumford deal - Stock Titan
embecta Completes Acquisition of Owen Mumford Holdings Limited - GlobeNewswire
Embecta Corp. completed the acquisition of Owen Mumford Holdings Limited from Mark Owen, Adam Mumford, Ellen Owen, Kim Priddis,Nancy Millington and others. - marketscreener.com
Embecta Corp stock (US29082K1051): Shares slide after conference update - AD HOC NEWS
Levi & Korsinsky Announces Investigation of Securities Claims Against Embecta Corp. (EMBC) - GlobeNewswire
S&P Global Ratings Cuts Credit Rating on Embecta (EMBC) After Revenue Decline - Insider Monkey
Transcript : Embecta Corp. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03 - marketscreener.com
Why Embecta's (NASDAQ:EMBC) Earnings Are Better Than They Seem - Yahoo Finance
EMBC Investor Alert: Levi & Korsinsky Investigates Embecta Corp. (EMBC) for Potential Securities Fraud - Morningstar
Embecta downgraded by S&P on demand weakness, market share loss - Investing.com South Africa
Embecta stock rating held at Neutral by BTIG after investor meetings By Investing.com - Investing.com
Embecta Corp Stock (EMBC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):